RUNX1/ETO, the fusion protein resulting from the chromosomal translocation t(8;21), is one of the most frequent translocation products in acute myeloid leukemia. Several in vitro and in vivo studies have shown that the homo-tetramerization domain of ETO, the nervy homology region 2 (NHR2), is essential for RUNX1/ETO oncogenic activity. We analyzed the energetic contribution of individual amino acids within the NHR2 to RUNX1/ETO dimer-tetramer transition and found a clustered area of five distinct amino acids with strong contribution to the stability of tetramers. Substitution of these amino acids abolishes tetramer formation without affecting dimer formation. Similar to RUNX1/ETO monomers, dimers failed to bind efficiently to DNA and to alter expression of RUNX1-dependent genes. RUNX1/ETO dimers do not block myeloid differentiation, are unable to enhance the self-renewal capacity of hematopoietic progenitors and fail to induce leukemia in a murine transplantation model. Our data reveal the existence of an essential structural motif (hot spot) at the NHR2 dimertetramer interface, suitable for a molecular intervention in t(8;21) leukemias.
Introduction
Chromosomal translocations are frequent events during malignant cell transformation, particularly during leukemogenesis. 1 The translocation t (8;21) , one of the most frequent chromosomal anomalies in acute myeloid leukemia, involves the RUNX1 gene (also known as AML1, CBFα2, or PEBP2αB) on chromosome 21 and the ETO gene (also known as MTG8 or RUNX1T1) on chromosome 8. The ubiquitously expressed RUNX1 is a transcription factor and belongs to the key regulators of hematopoietic cell differentiation. 2 The fusion protein RUNX1/ETO contains the DNA-binding domain (Runt, RHD) of the RUNX1 transcription factor but lacks the C-terminal transactivation sequence that is replaced by almost the entire ETO protein. Two forms of RUNX1/ETO co-exist in AML-leukemia samples: the originally discovered full length RUNX1/ETO and a splice variant called RUNX1/ETO9a, which lacks 178 amino acids at the C-terminus. Only RUNX1/ETO9a does not require cooperative events for inducing leukemia development in mice. 3, 4 We and others have shown that RUNX1/ETO has a modular structure. Besides the Runt domain, RUNX1/ETO contains four functional domains, which are generally referred to as nervy homology region (NHR) NHR1-4. The NHR domains serve as docking interface for a variety of different proteins including the E-protein HEB 5, 6 , the apoptosis related protein SON 7 and nuclear co-repressor proteins like N-CoR, SMRT, mSIN3A and MTGR1, as well as histone deacetylases (HDACs). [8] [9] [10] [11] In addition, the NHR2 domain mediates tetramer formation through hydrophobic and ionic/polar interactions. Two α-helices align in a head-to-tail fashion to form an anti-parallel dimer. Two dimers subsequently are positioned on top of each other in a sandwich like fashion. The total interaction area comprising all contact points of the four alpha helices is about 10.000 Å 2 . Substitution of seven leucines within the NHR2 sequence by arginine or glutamate was reported to disrupt the tetramer into four functionally inactive RUNX1/ETO monomers. 12 Similarly, destabilization of the RUNX1/ETO complex by intercalating polypeptides or deletion of the NHR2 domain fully abrogates the oncogenic properties of RUNX1/ETO arguing for a central role of NHR2-mediated oligomerization in RUNX1/ETO-4 driven leukemogenesis. [12] [13] [14] These studies however did not study the leukemogenic properties of RUNX1/ETO dimers.
As several reports have shown that RUNX1/ETO activity is required for both the onset and the maintenance of the leukemic phenotype 15, 16 , interference with RUNX1/ETO tetramer formation represents an attractive strategy for a molecular intervention. However, the large interaction area ascribed to the oligomerization domain makes this approach rather demanding. Increasing evidence suggests that the stability of protein-protein interfaces can depend on critical amino acids (hot spots), which contribute to a large fraction of the binding energy at a particular interface and are often surrounded by energetically less important residues. [17] [18] [19] Consequently, disruptors or inhibitors of protein-protein interaction do not necessarily need to target the entire interacting surface, but rather could be designed to address only those residues located at the hot spots.
The intention of our study was to identify amino acids that disrupt RUNX1/ETO tetramers into two dimers to analyze whether this would also abrogate RUNX1/ETO function. Therefore, we used computer based molecular modeling to evaluate the distribution of the binding free energy along the surface of the NHR2 dimer. Five amino acids were found to form a hot spot at the NHR2 dimer-tetramer interface which contributed largely to NHR2 tetramer formation and stability. Mutation of these critical amino acids blocks dimer-tetramer transition and abrogates RUNX1/ETO function, including induction of leukemia in vivo.
Material and Methods

MM-GB/SA calculations and free energy decomposition
Molecular dynamics simulations to generate snapshots required for the MM-GB/SA calculations were performed with the AMBER 8 suite of programs 20 together with the forcefield as described by Cornell et al 21 using modifications suggested by Simmerling et al. 22 Further details are provided in the Supplemental Data.
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Expression constructs and site directed mutagenesis
For transient and stable expression RUNX1/ETO, mutants and deletion constructs thereof were cloned into the retroviral vector MSCV. Amino acid substitutions were generated by standard methodologies. The expression plasmid pMigR1-REtr was kindly provided by DongEr Zhang (Scripps Research Institute, La Jolla, CA, USA). The composition of all constructs was confirmed by DNA sequencing.
Size exclusion chromatography and circular dichroism (CD) spectroscopy
Cellular extracts from 293T cells transfected with RUNX1/ETO expression plasmids were fractionated by size-exclusion chromatography and analyzed by western blotting as described before. 10 CD spectroscopy of the 95 amino acids long NHR2 recombinant proteins was performed using a Jasco CD spectrometer. Further details are given in the Supplemental Data.
Sedimentation velocity measurements.
Sedimentation velocity experiments were conducted with 300 µl samples at protein concentrations of 15 or 30 µM on an Optima XL-A centrifuge (Beckman Coulter Instruments, CA). Data was collected at a wavelength of 280 nm for the WT NHR2 or at 230 nm for the NHR2 mutant m5 and analyzed with SEDFIT and SEDPHAT. 23, 24 Further details are given in the Supplemental Data. Murine lin-depleted progenitor cells were maintained in RPMI supplemented with 10% FCS, 10ng/μl mIL-3, 50ng/μl mIL-6 and 50ng/μl mSCF. Retroviral transduction was performed as described before. 25 Stable transduced cell lines were purified by cell sorting (FACS-Aria, BD Pharmingen, Heidelberg, Germany).
ABCD assay and EMSA
Apoptosis, differentiation assay and cell cycle analysis
Four days after transduction, the percentage of apoptotic U937 cells was determined using 
Results
Molecular dynamics simulations and free energy decomposition reveal a spatially clustered arrangement of amino acid hot spots at the interface of the NHR2 tetramer
To identify critical amino acids at the interface of the NHR2 tetramer that contribute most to tetramer formation, we performed molecular dynamics simulations and Molecular Mechanics
Generalized Born Surface Area (MM-GB/SA) calculations combined with a free energy decomposition on a per-residue level using the coordinates of the crystal structure of the NHR2 tetramer. 12 Calculations of this type have previously been used successfully by us 27 and others 28, 29 to characterize the origin of binding in terms of contributions from structural subunits of the binding partners. The MM-GB/SA calculation disclosed five residues (W498, W502, D533, E536, W540) whose energy pattern suggested a strong contribution to the stabilization of the NHR2 tetramer structure ( Figure 1A , Figure S1 ). These residues are located within the inner hydrophobic side of each alpha-helical stretch of the tetramer at positions "a", "d" and "g" in the heptad helical wheel ( Figure 1B ) and are conserved among all ETO homologues ( Figure S2 ). The anti-parallel orientation of helices C1 and C2 in the NHR2 dimer places W498 and W502 in close proximity to residues D533, E536 and W540, resulting in a spatially compact arrangement of hot spot residues. These residues are not located in the center of the interface, which is rather flat, but at its edges. Here, the protein topography is rugged, and the hot spot arrangement embraces the largest indentation found in the binding epitope with a volume of about 269 Å 3 ( Figure 1C ). Upon tetramer formation with helix C3 and C4, this conformation yields a tight fitting complex structure that is complementary in shape. Either one of residues D533, E536, and W540, located at the Cterminal helix end, e.g., of C2 is involved in interactions with two residues mainly located at the C-terminal helix end of C3 ( Figure 1D ). D533 forms buried salt-bridges with R492 of C4 located at the N-terminal helix end, e.g., of C1 forms an indentation into which L526 of C3 inserts ( Figure 1E ). Conversely, W498 packs into an indentation formed by the hydrophobic parts of the side-chains of L526, C529 and Q530 located on C3. As C3 and C4 are related to C1 and C2 by an approximate two-fold rotational symmetry, the above interaction patterns occur four times in the tetramer interface. Summarizing, these results suggest the existence of amino acids clusters that form functional epitopes within the structural interface of the NHR2 tetramer.
Substitution of amino acids within the tetramerization hot spot disrupts NHR2 tetramer formation
To study the biochemical properties and functional consequences of amino-acid substitution within the NHR2 hot spot domain we introduced alanine substitutions at amino acid positions 498 (W498A), 502 (W502A), 533 (D533A), 536 (E536A) and position 540 (W540A) of RUNX1/ETO to generate a mutant termed m5. As a control, alanine mutations were introduced at amino acid positions with low energy contribution to tetramer stability, namely positions 512 (I512A), 516 (V516A), 519 (T519A), 523 (L523A) and 526 (L526A) (cm5 mutant, Figure 1B ). We also introduced these mutations within a C-terminal truncated version of RUNX1/ETO (REtr) lacking the NHR3 and NHR4 domains since REtr has been shown previously to block differentiation of myeloid cells in vitro and to induce leukemia in mice. 
). In contrast the migration profile of REtr-cm5 was similar to that of wild type REtr, suggesting that REtr-cm5 exists as a tetramer. We also used a mutant, in which the α -helical structure was partially abrogated by leucine to arginine or glutamic acid mutations (REtrm7). 12 As predicted, the elution profile of REtr-m7 was similar to that of REtr monomers lacking the NHR2 domain (REtr-dNHR2) and eluted in fractions of low molecular weight as RUNX1/ETO monomers. 12 From the elution profiles of the different RUNX1/ETO variants it becomes apparent that the elution profile of REtr-m5 peaks between the wild-type tetrameric (REtr) and the monomeric (REtr-m7) forms ( Figure 2B ), most likely reflecting a dimeric conformation. Furthermore the finding that two differentially tagged REtr-m5 molecules retain the ability to co-immunoprecipitate implies that the dimeric conformation is stable in vivo ( Figure S3 ). To investigate the biophysical properties of the m5 mutant in greater detail, a wild type NHR2-only domain and the corresponding NHR2-m5 mutant were expressed in bacteria as His-fusion proteins and purified by Ni-affinity chromatography. With these proteins, we performed sedimentation velocity measurements to clarify the oligomerization state of the NHR2-m5 mutant in solution. We found that the NHR2-m5 mutant migrates at a sedimentation coefficient of 2.8 S as a single peak corresponding to 77% -86% of the material loaded (Table 1 and Figure S4 ). Based on this observation the molecular mass for the NHR2-m5 dimer was calculated to be approximately 24 kDa, which is closed to the theoretical mass of 22.2 kDa estimated for a dimer of 2 x 95 amino acids. A similar analysis for wild type NHR2 confirmed the multimeric structure of this protein (data not shown).
Furthermore, we characterized the secondary structure of the NHR2-m5 mutant by circular dichroism (CD) spectroscopy. The recombinant protein exhibited typical features of an alphahelical domain with ellipticity minima at 208 and 222 nm, similar to the wild type NHR2 polypeptide ( Figure 2C ). The content of alpha-helical secondary structure was identical for NHR2 and NHR2-m5 at room temperature (64% helical content for NHR2 versus 63% for NHR2-m5), thus indicating that the amino acid exchanges in NHR2-m5 do not disturb the α-helical structure of the NHR2 domain. Furthermore, we characterized the thermal stability of NHR2-m5 by thermal denaturation and renaturation experiments and subsequently 10 monitored the changes in ellipticity by CD spectroscopy. In agreement with the values determined previously 12 , we found that the melting point for the NHR2-only protein was 85°C, with a sharp transition between the folded and unfolded state, which is indicative of a strong cooperativity between the alpha helices in tetramer stabilization ( Figure 2D ). In comparison, the melting point of the NHR2-m5 mutant protein was 60°C, with a broader transition between the folded and the unfolded state of the helix suggesting a less tight association between the NHR2-m5 α -helical domains.
RUNX1/ETO-m5 exhibits reduced DNA-binding capacity and fails to activate endogenous RUNX1/ETO target genes
RUNX1/ETO has been shown to downregulate PU.1 and RUNX3 (R3) gene expression by direct binding to RUNX1 consensus sequences in the promoter region of both genes. 30, 31 Since the leukemogenic properties of REtr critically depend on its DNA-binding capacity 13 , we analyzed the binding properties of REtr-m5 to double stranded DNA oligo-nucleotides containing either the PU.1 or the RUNX3 RUNX1 binding site using the avidin-biotin complex DNA-binding (ABCD) assay. A strong DNA-binding activity to the R3 and PU.1 binding sites was found in cellular extracts of transfected 293T containing REtr ( Figure 3A and 3B). The binding was specific since no binding was found to the empty magnetic beads used to pulldown the biotin-labeled oligonucleotides nor to oligos containing mutated RUNX1 binding sites ( Figure 3E ). In contrast we found only a weak binding to both oligonucleotides when cell extracts containing REtr-m5 were analyzed in this binding assay. Also monomeric forms of REtr (REtr-dNHR2) did not bind to the oligos ( Figure 3A and 3B), confirming the results of others who have shown that tetramerization of RUNX1/ETO is required for specific DNAbinding. 32 Compared to the binding strength of the REtr tetrameric form, the dimeric and monomeric forms of REtr displayed a 40-fold reduction in binding affinity to the DNA oligos ( Figure 3C and 3D).
We also introduced the m5 mutations into full length RUNX1/ETO and tested its DNA-binding capability as mentioned above. Full length RUNX1/ETO did bind specifically to the R3 11 oligonucleotide, whereas a mutant of R3 lacking the RUNX1 binding sites was not bound by RUNX1/ETO and DNA-binding was undetectable in extracts containing the PML/RARα protein ( Figure 3E ). Similar to the findings with REtr-m5, binding of RE-m5 to the R3 and PU.1 oligonucleotides was barely detectable and could be visualized only after extended exposure times. In contrast to the DNA-binding defect observed with the dimeric RE-m5 molecule, the RE-cm5 control mutant did bind to the R3 and PU.1 oligonucleotides, supporting our previous conclusions that REtr-cm5 forms a tetramer ( Figure 3F ). Also coexpression of the cofactor CBFß, which enhances DNA-binding of RUNX1 33 , did not improve REtr-m5 binding to DNA (data not shown). Similar to the observations of others 32 , the monomeric form of RUNX1/ETO (RE-dNHR2) and a DNA-binding defective mutant of RUNX1/ETO (RE-L148D) failed to bind to the R3 oligonucleotide. Loss of RE-m5 DNAbinding was also observed by EMSA analysis using a radioactive labeled RUNX1 high affinity oligonucleotide ( Figure 3G ). Subsequently we examined the ability of REtr-m5 to interfere with RUNX1/ETO target gene expression, since this property of RUNX1/ETO depends on tetramerization. 12 We transduced U937 cells with either wild type REtr or REtrm5. After transduction, cells were sorted for eGFP and analyzed for expression of RUNX1/ETO target genes by western blotting. The RUNX1/ETO target genes TrkA, c-jun and p-21 were upregulated in the presence of the tetrameric form of REtr, but their expression was unaffected in cells expressing the dimeric REtr-m5 protein ( Figure 3H ). Thus our cumulative evidence suggests that REtr-m5 lacks substantial DNA-binding activity and does not alter the expression pattern of RUNX1/ETO target genes.
RUNX1/ETO tetramers but not dimers trigger apoptosis and block cytokine-induced myeloid differentiation
Inhibition of granulocytic and monocytic differentiation as well as cell cycle arrest and induction of apoptosis are hallmarks of RUNX1/ETO activity. 34 To investigate the dependence of these biological effects on the structural state of RUNX1/ETO, the monomeric To investigate the relevance of tetramer formation for cell cycle arrest in more detail, K562 cells expressing either the tetrameric, dimeric or monomeric forms of RUNX1/ETO were generated. Expression of full length RUNX1/ETO in these cells leads to a profound arrest in the G1 phase of the cell cycle. 3 In agreement with our previous observations, only the tetrameric form of RUNX1/ETO induced a robust cell cycle arrest in G1, while the cell cycle arrest in RE-m5 or RE-dNHR2 cells was similar to that of mock transduced cells ( Figure 4E ).
Taken together expression of the tetrameric but not the dimeric form of RUNX1/ETO accounts for a perturbed cell cycle distribution and apoptosis.
RUNX1/ETO is known to block VitD3/TGFß and ATRA triggered monocytic and granulocytic differentiation. To test the effect of the various RUNX1/ETO forms on myeloid differentiation, transduced U937 cells were stimulated with VitD3/TGFß or ATRA two days after transduction ( Figure 4F and 4G). We monitored monocytic differentiation by FACS based on CD14 expression 24 hours after VitD3/TGFß administration. As expected about half of the eGFP- 13 positive RUNX1/ETO expressing cells remained CD14 negative, whereas the population of non-transduced cells in the same culture was almost completely positive for CD14 ( Figure   4F ). The tetrameric forms, RE and RE-cm5, both showed similar properties, while RE-m5
and RE-dNHR2 failed to block monocytic differentiation, as determined by equal amounts of CD14+ cells in the eGFP-positive and negative fractions ( Figure 4F and 4G) . Similar results were obtained upon ATRA-induced myeloid differentiation. In this case cell differentiation was measured by CD11b-staining three days after ATRA administration. Again only cells expressing the tetrameric form of RUNX1/ETO (in this case REtr) showed a strong reduction in cellular differentiation levels while mock-transduced and REtr-m5 transduced cells did not show any block in myeloid differentiation ( Figure 4G ). Taken together, the dimeric form of RUNX1/ETO (m5) behaved similarly to the monomeric form (dNHR2) in that both have lost the capacity to block myeloid cell differentiation.
RUNX1/ETO-m5 fails to trigger self-renewal of HSCs
RUNX1/ETO is known to induce self-renewal of immature hematopoietic cells without affecting their lymphoid and myeloid differentiation potential. [35] [36] [37] We used this property of RUNX1/ETO to test the effect of the NHR2 mutations in primary hematopoietic cells. As a readout system for REtr function in vitro, we made use of a clonogenic assay, which critically depends on RUNX1/ETO tetramer formation. 12, 26 As expected, expression of REtr in murine progenitor cells induced a strong clonogenic activity as measured by serial replating of REtr transduced progenitor cells ( Figure 5A ). In contrast, constructs deficient in DNA-binding activity (REtr-L148D) or tetramer formation (REtr-deltaNHR2 and REtr-m7) completely failed to enhance the clonogenic activity of hematopoietic progenitors. We found that the alanine substitutions in REtr-m5 completely abolished the clonogenic properties of REtr, which thus behaves like the clonogenic inactive forms of REtr, while mutants with partial amino acid substitutions in the hot spot (m2, m3, Figure S2 ) retained some residual replating capacity ( Figure 5A ).
RUNX1/ETOtr dimers fail to induce leukemia in mice
In contrast to full length RUNX1/ETO, the truncated form of the oncoprotein (REtr) has been shown to induce leukemia in mice. in REtr transplanted mice compared to stable levels in REtr-m5 transplanted mice (Table   S1 ). In addition, mice transplanted with REtr expressing cells showed increased numbers of white blood cells (WBC), and reduced hematocrit (HCT). In contrast, the body weight, WBC,
and HCT values of animals transplanted with REtr-m5 were similar to those transplanted with non-transduced cells ( Figure 5C ).
Similar to previous reports 3 , the bone marrow of REtr mice contained mainly immature cells as estimated by the lack of the differentiation markers Gr-1, CD11b, B220 and CD3 in the eGFP-positive cell fraction ( Figure 5D ). In contrast, the vast majority of eGFP-positive cells 
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Discussion
We have used binding free energy calculations together with a free energy decomposition to identify essential amino acids involved in RUNX1/ETO dimer-tetramer transition. These methods have been previously used among others to define amino acid hot spots at the interaction surfaces of H-Ras/C-Raf1 and H-Ras/RalGDS 27 and to define amino acid recognition by aspartyl-tRNA synthetase. 28 The computational analysis of NHR2 suggested an uneven distribution of effective binding energy along the tetramer interface and identified five critical amino acids that provide more than 50% of the binding energy to dimer-tetramer transition. According to the crystal structure of the NHR2 homo-tetrameric α -helical bundle,
we have identified a hot spot for RUNX1/ETO tetramerization at both edges of each dimer.
Notably, not all amino acids contributing to the hot spot were clustered on one alpha helix.
Rather the hot spot is shaped by the close spatial proximity of W498 and W502 to D533, E536 and W540 once two α -helical monomers associate in an anti-parallel orientation to form a dimer. Since our computational analysis was focused on the dimer-tetramer transition, leucine residues, which largely contribute to the stability of each NHR2 dimer, were not scored as essential amino acids for tetramer formation. Among the five amino acids involved we found tryptophan and aspartate, two amino acids that are capable of forming multiple types of favorable interactions, such as π-π-, hydrogen bonding and hydrophobic interactions and are frequently found in hot spots of various protein-protein interactions. 18 The relevance of these amino acids in tetramer stabilization is strengthened by the fact that salt-bridge networks often stabilize complexes of alpha helical stretches by reducing their thermal motion, which results in increased thermostability. 38 The amino acid residues at the NHR2 hot spot are located at the "a", "d" and "g" positions of the alpha helix at the inner side of the tetramer and become deeply buried in the interface. Moreover, these amino acids cluster around a cleft on the dimer surface, identified as the largest indentation on the dimer surface.
Alanine substitutions at these five positions destroyed tetramer formation, resulting in RUNX1 is known to bind DNA as a heterodimer and to undergo a conformational shift upon binding, which is further stabilized after heterodimerization with CBFß. 40 CBFß is known to enhance the DNA-binding affinity of the Runt domain and binds more efficiently to the DNAbound Runt domain than to the Runt domain alone. 41, 42 In our study however, co-expression of CBFß did not increase the DNA-binding affinity of the RUNX1/ETO dimer, probably reflecting the poor association of the dimer with DNA.
RUNX1/ETO tetramers have been shown to bind preferentially to DNA stretches containing two RUNX1 binding sites. 32 Although the RUNX3 and PU.1 oligonucleotides used in our study did contain two RUNX1 consensus-binding sites, RE-m5 or REtr-m5 failed to bind to these oligonucleotides. One can anticipate that the antiparallel orientation of both (data not shown), and to enhance the clonogenic potential of primary murine bone marrow cells. 26 The tetrameric configuration of RUNX1/ETO is reminiscent of that described for the BCR/ABL oncoprotein. In BCR/ABL, two anti-parallel oriented monomers associate to form a coiled coil dimer and two dimers assemble into a tetramer. In the tetrameric configuration, the functional domains of two opposite dimers are placed in close proximity to each other (~24 Ǻ ), whereas in the dimer, the antiparallel orientation of the monomers places the functional domains of each monomer around 60 Ǻ apart from each other. 44 In analogy, only the tetrameric configuration in RUNX1/ETO may provide the spatial configuration required for tight DNA-binding. 19 We propose the NHR2 tetramerization domain of RUNX1/ETO as a challenging but reasonable and promising target for a molecular intervention in t(8;21) leukemias. Although protein-protein interfaces were originally thought to be difficult targets for drug development, recent advances in the understanding of structural constraints at interacting surfaces in combination with structural and mutational analysis has allowed for the development of small-molecule mimics of hot spots that have been found to inhibit protein-protein interactions. [45] [46] [47] [48] Also effective modulation of protein-protein interactions has been described for small-molecules binding to clefts or grooves at interface regions. 49, 50 It appears promising that the NHR2 hot spot is located around the largest indentation on the dimer surface.
Furthermore, the two-fold rotational symmetry of the RUNX1/ETO dimer creates two hot spot regions per dimer, which are expected to act as two independent ligand-binding sites for appropriate modulators, thus enhancing their specific effect. As oligomerization events represent an important subset of protein-protein interactions in leukemia [51] [52] [53] , the rational approach adopted in our work could be further expanded to other oligomerization domains for target evaluation and the development of novel therapeutic approaches. 86% a Sedimentation profile for the NHR2-m5 protein at two different loading concentrations. Data was analyzed using the c(s) continuous distribution of Lamm equation solutions with SEDFIT and SEDPHAT. b The molecular mass estimation was obtained using the optimal frictional ratio (f/f 0 ) with SEDFIT. c The ratio f/f 0 is the frictional coefficient of a particle of a given axial ratio divided by the frictional coefficient of a sphere of the same volume. d Root mean square deviation of the global fit in units of absorbance (OD). e The weight percent contribution of the majority species was obtained by integration of a continuous sedimentation coefficient distribution from ~1.5 to ~3.5 S with SEDFIT. 
